Novartis Pharmaceuticals [clinicaltrials_resource:6c46b84d98e818ca1d19723a0f4ae0c2]
Novartis Pharmaceuticals [clinicaltrials_resource:001628863afd109171f74cd041c5f26c]Novartis [clinicaltrials_resource:013736ab2771601535640119d9cc093b]novartis pharmaceuticals [clinicaltrials_resource:01aab4517d125170a3a2af41550176d6]Novartis Pharmaceuticals [clinicaltrials_resource:032a542f5f373a2a2175875c8e3fef00]Novartis Pharmaceuticals [clinicaltrials_resource:0353ac50ee866bc0c31a15976d0a2b08]Novartis Pharmaceuticals [clinicaltrials_resource:0393de68319124e5840c236caca36a80]Novartis Pharmaceuticals [clinicaltrials_resource:04637651e90329cc8fdac0353f3c36d6]Novartis Pharmaceuticals [clinicaltrials_resource:04eb76defc23499a27b4a4536b5936c4]Novartis Pharmceuticals [clinicaltrials_resource:055ad40b9c95f47ee6ac47bf0f2d3a70]Novartis Pharmaceuticals [clinicaltrials_resource:07e33fb210742568bc294b954db0123b]Corinne Wild, PhD [clinicaltrials_resource:0850258ea8908ab562cf8f7b22ace81f]Novartis Pharmaceuticals [clinicaltrials_resource:0e6c6729f749c38f858e2284301b04cd]Novartis Pharmaceuticals [clinicaltrials_resource:1040b0225b3ba2f82bc7e173039eda3f]Novartis Pharmaceuticals [clinicaltrials_resource:10ead8146d04eed2589ea5c33766f37f]Novartis Pharmaceuticals [clinicaltrials_resource:1128475cf55618b71d85a8f7f0f9f1a8]Edwin Choy, MD, PhD [clinicaltrials_resource:118faf8868cb48968153c67e48cb03a2]Novartis Pharmaceuticals [clinicaltrials_resource:141d663aa5d421da5f040ab6cfdc5eac]Abraham Kroon, MD, PhD [clinicaltrials_resource:1526800ff7e961797416facd992a3b32]Stephanie Petrone, SCRS [clinicaltrials_resource:17790ed7739515584fa820958baa24dc]Novartis Pharmaceuticals [clinicaltrials_resource:17d6e2fd6f56cc6bab89e3c811773106]Novartis . [clinicaltrials_resource:196f37ed9568136f06d282b1608fe8a3]Novartis Pharmaceuticals [clinicaltrials_resource:1baa1fdf2d0539a26d9c4795b26465c3]Novartis Pharmaceuticals [clinicaltrials_resource:1c43b20a76bfedd919830a71a8d1f686]Novartis Pharmaceuticals [clinicaltrials_resource:1c9bc1c84e3a62d3365116895e84e066]Call 1‐877‐CTLILLY (1‐877‐285‐4559) or 1‐317‐615‐4559 Mon ‐ Fri 9 AM ‐ 5 PM Eastern time (UTC/GMT ‐ 5 hours, EST) [clinicaltrials_resource:1cc7c4012ce8bdf16e5a95cf4e5bf918]Novartis Pharmaceuticals [clinicaltrials_resource:1cd47cb8f17849ef7ce6bf240de44994]Novartis Pharmaceuticals [clinicaltrials_resource:1e5f220073a0d75bab1911afd48b953e]Novartis Pharmaceuticals [clinicaltrials_resource:1ef7918956736503ea4d59e753885a9a]Novartis Pharmaceuticals [clinicaltrials_resource:210a40d1285587699721c27fc31b5ab2]Novartis Pharmaceuticals [clinicaltrials_resource:221137a7c4daad203027e9bb5dcde610]Robert Knight, MD [clinicaltrials_resource:240a71094cfc146fcd61c192326263f6]Novartis Pharmaceuticals [clinicaltrials_resource:24b04f8e2c8c2f28ff8e4afb57e69b46]Novartis Pharmaceuticals [clinicaltrials_resource:270dca5f7ec922c621e2d6c6120536ce]Andrzej Jakubowiak [clinicaltrials_resource:274baae1d5a2763a948202ebe2fcd212]Novartis Pharmaceuticals [clinicaltrials_resource:28a1b36bc9a5cae141b0346a7ebaad68]Novartis Pharmaceuticals [clinicaltrials_resource:28e3bed31c31bd9e070818cad8a0e3d3]Novartis Pharmaceuticals [clinicaltrials_resource:29dbc98db50ae8138f704d7ccd66c84a]Brian Elliott, MD [clinicaltrials_resource:2a2ab08fda296b693ada7676b9d5699c]Novartis Pharmaceuticals [clinicaltrials_resource:2aa5bb1f5c4cd3af06409fd455d21be2]Novartis Pharmaceuticals [clinicaltrials_resource:2acfad5c63fd988e0416447ca7540ac0]
affiliation [clinicaltrials_vocabulary:affiliation]
clinicaltrials:NCT00045942STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea [clinicaltrials:NCT00050635]Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer [clinicaltrials:NCT00056446]clinicaltrials:NCT00099268Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy [clinicaltrials:NCT00108108]Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease [clinicaltrials:NCT00134979]clinicaltrials:NCT00142298clinicaltrials:NCT00171704Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer [clinicaltrials:NCT00171847]Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer [clinicaltrials:NCT00219271]Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment [clinicaltrials:NCT00237198]Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer [clinicaltrials:NCT00237211]Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients [clinicaltrials:NCT00239798]clinicaltrials:NCT00242580Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer [clinicaltrials:NCT00247663]A Study of Letrozole in the Treatment of Endometrial Cancer [clinicaltrials:NCT00333086]clinicaltrials:NCT00423085clinicaltrials:NCT00545272Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies [clinicaltrials:NCT00670592]clinicaltrials:NCT00670930clinicaltrials:NCT00719264clinicaltrials:NCT00770601clinicaltrials:NCT00853827clinicaltrials:NCT00870584clinicaltrials:NCT00886769clinicaltrials:NCT00889863clinicaltrials:NCT00891046clinicaltrials:NCT00902304Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects [clinicaltrials:NCT00964665]Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence [clinicaltrials:NCT00987545]clinicaltrials:NCT01202903Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria [clinicaltrials:NCT01228344]Safety of CHIR-258 (TKI258) in Advanced Solid Tumors [clinicaltrials:NCT01270906]Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients [clinicaltrials:NCT01320358]clinicaltrials:NCT01348100Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma [clinicaltrials:NCT01362621]clinicaltrials:NCT01404325Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors [clinicaltrials:NCT01529619]Pharmacokinetics of Agomelatine in Patients With Liver Impairment [clinicaltrials:NCT01531309]A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) [clinicaltrials:NCT01542866]
collaborator [clinicaltrials_vocabulary:collaborator]
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms [clinicaltrials:NCT00005073]Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer [clinicaltrials:NCT00006368]Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer [clinicaltrials:NCT00006370]EPO906 Therapy in Patients With Advanced Colorectal Cancer [clinicaltrials:NCT00035087]EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer [clinicaltrials:NCT00035100]EPO906 Therapy in Patients With Prostate Cancer [clinicaltrials:NCT00035113]EPO906 Therapy in Patients With Advanced Breast Cancer [clinicaltrials:NCT00035126]EPO906 Therapy in Patients With Advanced Melanoma [clinicaltrials:NCT00035165]EPO906 Therapy in Patients With Advanced Kidney Cancer [clinicaltrials:NCT00035243]Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis [clinicaltrials:NCT00035997]A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis [clinicaltrials:NCT00036413]clinicaltrials:NCT00045942Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture [clinicaltrials:NCT00046254]Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma [clinicaltrials:NCT00046748]HORIZON-PFT: Pivotal Fracture Trial [clinicaltrials:NCT00049829]clinicaltrials:NCT00050011EPO906 in Carcinoid and Other Neuroendocrine Tumors [clinicaltrials:NCT00050349]STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea [clinicaltrials:NCT00050635]Pediatric Epilepsy Study [clinicaltrials:NCT00050934]Pediatric Epilepsy Study [clinicaltrials:NCT00050947]clinicaltrials:NCT00051636Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 [clinicaltrials:NCT00052013]Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer [clinicaltrials:NCT00056446]Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions [clinicaltrials:NCT00061750]Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias [clinicaltrials:NCT00061763]Bisphosphonate Treatment of Osteogenesis Imperfecta [clinicaltrials:NCT00063479]The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy [clinicaltrials:NCT00063609]Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions [clinicaltrials:NCT00067080]Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS) [clinicaltrials:NCT00072709]clinicaltrials:NCT00076336Pediatric Hypothalamic Obesity [clinicaltrials:NCT00076362]clinicaltrials:NCT00079937Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia [clinicaltrials:NCT00081926]Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia [clinicaltrials:NCT00084071]Non-small Cell Lung Cancer Study US75 (Z-PACT) [clinicaltrials:NCT00086268]A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy [clinicaltrials:NCT00087659]Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients [clinicaltrials:NCT00088582]clinicaltrials:NCT00088595A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease [clinicaltrials:NCT00088608]clinicaltrials:NCT00093600
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Novartis Medical Director, Novartis Pharmaceuticals [clinicaltrials_resource:1675c4f8e6a8c379427b54fb9911d02d]Novartis External Affairs, Novartis Pharmaceuticals [clinicaltrials_resource:38551fb18f5d6880826473716b8d62af]Novartis, Novartis Pharmaceuticals [clinicaltrials_resource:3bda374156123494eeaf904fa8283265]Study Director Novartis Pharmaceuticals, Novartis Pharmaceuticals [clinicaltrials_resource:3db38e180176d24ce72d6c63a2d4600e]Study Diorector, Novartis Pharmaceuticals [clinicaltrials_resource:58c857bb48ff5e6a833a8206ce81d5ad]Medical Affairs, Novartis Pharmaceuticals [clinicaltrials_resource:5fe542da9ea1c1c792b39524f7153e9c]Medical Department, Novartis Pharmaceuticals [clinicaltrials_resource:63ff9c74f4866181951d3667e2551e9a]External Affairs, Novartis Pharmaceuticals [clinicaltrials_resource:698dd4655e3caf416cbabecaf4669bd4]Clinical Disclosure Office, Novartis Pharmaceuticals [clinicaltrials_resource:c5def792ed4603428d9a60acb7fdae99]e, Novartis Pharmaceuticals [clinicaltrials_resource:e4c85fab81818b1f3753033f9cbddc09]Study Director, Novartis Pharmaceuticals [clinicaltrials_resource:ffa6483e85c87ecd04ac6d3cf18df04b]
organization [clinicaltrials_vocabulary:organization]
Novartis Pharmaceuticals [clinicaltrials_resource:6c46b84d98e818ca1d19723a0f4ae0c2]
Bio2RDF identifier
6c46b84d98e818ca1d19723a0f4ae0c2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:6c46b84d98e818ca1d19723a0f4ae0c2
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:6c46b84d98e818ca1d19723a0f4ae0c2
title
Novartis Pharmaceuticals
@en
type
label
Novartis Pharmaceuticals [clinicaltrials_resource:6c46b84d98e818ca1d19723a0f4ae0c2]
@en